Sucralose, an artificial sweetener extensively utilized across the globe in countless food and beverage products, has been the subject of intensified scientific scrutiny following recent laboratory investigations into its potential biological impacts. Marketed prominently under brand names like Splenda®, this high-intensity sweetener provides sweetness without caloric content, making it a popular choice for individuals managing sugar intake. However, a specific chemical entity linked to sucralose, known as sucralose-6-acetate, became a focal point of concern after studies published in 2023 indicated its capacity to induce genetic damage in human cells and compromise the integrity of an in vitro model of the intestinal lining. These initial findings prompted significant discussion within the scientific community and among public health advocates, necessitating a deeper examination of sucralose’s overall safety profile, particularly in light of its widespread consumption.
The 2023 research, spearheaded by a team including corresponding author Susan Schiffman, an adjunct professor in biomedical engineering at North Carolina State University and the University of North Carolina at Chapel Hill, highlighted sucralose-6-acetate as a compound distinct from sucralose itself, yet chemically related. This particular derivative was reportedly found as an impurity during the manufacturing process of commercial sucralose samples, with concentrations observed reaching up to 0.67% in some analyses. Schiffman underscored the novelty of these findings, stating in 2023 that their work conclusively demonstrated the genotoxic nature of sucralose-6-acetate and confirmed its presence as a trace impurity in readily available sucralose products, even prior to ingestion and potential metabolic transformation.
Earlier investigations conducted by the same research group, published in 2018, had initially identified fat-soluble compounds in the urine and feces of rats administered sucralose. These observations led researchers to hypothesize that the sweetener was undergoing chemical modifications within the animal’s digestive system. Subsequent efforts by the team then isolated sucralose-6-acetate as one of the key compounds of interest, further fueling the inquiry into its origins and effects. However, it is critical to note that these early animal studies did not definitively prove that metabolism produced these compounds; their presence could also be attributed to impurities already existing in the sucralose administered to the rats. This distinction became a point of contention and was later addressed in comprehensive regulatory assessments.
To evaluate the potential for cellular harm, the 2023 study involved exposing cultured human blood cells to sucralose-6-acetate in a controlled laboratory setting. These were in vitro experiments, meaning they were conducted outside a living organism, providing insights into potential biochemical interactions at the cellular level, rather than directly reflecting effects in humans consuming the sweetener. The findings from these experiments suggested a pattern consistent with genotoxicity, which is the ability of a chemical agent to damage the genetic material within a cell, potentially leading to mutations or other cellular dysfunctions. Specifically, the screening results indicated a molecular signature associated with breaks in DNA strands. Schiffman emphasized these results, stating that sucralose-6-acetate effectively fragmented DNA in the cells subjected to the chemical.
While such in vitro findings are crucial for identifying potential hazards, the leap from a laboratory observation to a definitive human health risk requires careful interpretation. Exposing isolated cells directly to a chemical at potentially high concentrations does not automatically translate to the same outcome in a complex biological system like the human body, where various protective mechanisms and metabolic pathways are at play. The 2023 experiments, therefore, did not establish that typical human consumption of sucralose would lead to DNA damage or other adverse health effects. This critical distinction between a demonstrated laboratory effect and a confirmed health risk in the context of everyday consumption is a cornerstone of toxicological assessment.
Beyond genotoxicity, the research team also explored the effects of sucralose and sucralose-6-acetate on the human intestinal lining, a vital barrier that regulates the passage of substances from the digestive tract into the bloodstream. Employing a laboratory model comprising human intestinal tissue, both compounds were found to compromise the integrity of this crucial barrier under the specific experimental conditions. Schiffman explained that this impairment resulted in what is commonly referred to as "leaky gut," where the intestinal wall becomes more permeable due to damage to the "tight junctions" that bind cells together. Such increased permeability could theoretically allow substances normally expelled from the body to enter the bloodstream, potentially leading to systemic issues.
Furthermore, the study examined how exposure to sucralose-6-acetate influenced gene activity within intestinal cells. The researchers reported an upregulation of genes associated with oxidative stress, inflammation, and carcinogenicity. Again, it is important to contextualize these findings: increased activity in genes related to a particular biological process does not equate to the direct manifestation of a disease, such as cancer. Rather, it indicates a cellular response or a predisposition, which may or may not translate into clinical outcomes in a living organism under normal exposure conditions.
A significant concern raised by the researchers involved the potential daily intake of sucralose-6-acetate without consumers’ awareness. Schiffman highlighted that the European Food Safety Authority (EFSA) maintains a "threshold of toxicological concern" (TTC) for all genotoxic substances, set at 0.15 micrograms per person per day. The 2023 study’s authors suggested that the trace amounts of sucralose-6-acetate detected in a single sucralose-sweetened drink could surpass this threshold, even before considering any amounts that might be formed as metabolites post-consumption. However, this comparison requires an important clarification: the TTC is a highly conservative screening tool, employed when detailed toxicity data are scarce, to identify chemicals requiring further investigation. Exceeding a TTC does not equate to demonstrating actual DNA damage or disease causation; it merely signals a need for more rigorous safety evaluations. It is also distinct from the acceptable daily intake (ADI) established specifically for sucralose, which represents an amount considered safe for daily, lifetime consumption.
Despite the caveats, the 2023 research team deemed their findings serious enough to advocate for a reevaluation of sucralose’s safety and regulatory status, with Schiffman explicitly advising individuals to avoid products containing the sweetener. This strong warning reflected the team’s position at the time, but subsequent, broader assessments have offered a more nuanced and often different overall conclusion regarding the safety of sucralose under its currently approved uses.
In a comprehensive reassessment published in February 2026, the European Food Safety Authority (EFSA) reaffirmed the acceptable daily intake (ADI) for sucralose at 15 milligrams per kilogram of body weight per day. Their experts concluded that estimated dietary exposure across various population groups remained below this safety threshold. The EFSA review meticulously considered the 2023 research, including the reported signals of DNA damage linked to sucralose-6-acetate. However, the expert panel ultimately judged the in vitro screening evidence to have limited relevance for their comprehensive safety assessment, especially when weighed against a broader body of evidence from laboratory, animal, and human studies. Consequently, the EFSA panel concluded that the use of sucralose as a food additive does not raise genotoxicity concerns. Similarly, in the United States, the Food and Drug Administration (FDA) continues to approve sucralose for use as a food sweetener, citing its own extensive safety assessment, which incorporated over 110 studies investigating potential toxicological effects, alongside human clinical research.
Further scientific contributions have added to this evolving understanding. A study published online in August 2026 in Food and Chemical Toxicology evaluated commercial-grade sucralose using a battery of genetic toxicity tests across various cell and animal models. The authors reported predominantly negative results in most assays, including those designed to detect mutations and chromosome damage. A study utilizing genetically modified mice also found no increase in the specific mutations under investigation. While one particular test, known as a comet assay, did detect DNA damage signals in certain tissues, the authors noted complexities in interpreting these specific results and ultimately concluded that the overarching findings did not indicate genotoxicity. It is worth noting the industry affiliations of several authors from this study, including Tate & Lyle and Intertek, which provides important context for the research. Crucially, this investigation tested commercial sucralose formulations rather than directly replicating the 2023 experiments with isolated sucralose-6-acetate, meaning the two studies addressed related, yet not identical, scientific questions.
Beyond concerns about DNA damage, other independent research has explored broader biological effects of sucralose, particularly its influence on physiological processes such as appetite and metabolism. These studies, while not investigating genotoxicity, contribute to a holistic understanding of how the sweetener interacts with the human body. For instance, a randomized study published in Nature Metabolism in March 2025 involved 75 young adults who consumed drinks containing sucralose, an equivalent sweetness amount of sugar, or plain water on separate occasions. Compared to sugar, sucralose intake was associated with increased self-reported hunger and elevated blood flow in the hypothalamus, a brain region integral to appetite regulation. Relative to water, sucralose also increased hypothalamic blood flow but did not alter hunger ratings. These observations reflect immediate physiological responses and do not provide evidence that sucralose causes sustained weight gain.
Another systematic review, published in August 2026, analyzed 23 randomized trials focusing on sucralose and cardiometabolic outcomes in healthy adults. The findings regarding blood sugar regulation were mixed, with some studies indicating unfavorable changes while others reported no discernible effect. The review’s authors raised legitimate questions about potential metabolic impacts, emphasizing that these inquiries into appetite and glucose regulation are distinct from the earlier claims concerning DNA damage.
A separate, unresolved issue identified by the EFSA review involves the potential degradation of sucralose under prolonged exposure to high temperatures, such as during baking or frying. Under certain heating conditions, chlorine atoms from sucralose may incorporate into other compounds, whose health effects remain largely undetermined. Consequently, the EFSA panel could not confirm the safety of a proposed expansion of sucralose’s use in specific baked goods and cautioned that similar uncertainties could arise during home cooking where temperatures and cooking times vary. This particular concern centers on novel compounds that might form during thermal processing, rather than confirming the specific sucralose-6-acetate findings from the 2023 study.
In conclusion, the scientific discourse surrounding sucralose and its safety profile is characterized by ongoing research and evolving understanding. While the 2023 study highlighted potentially significant effects of sucralose-6-acetate in controlled laboratory systems, subsequent, more comprehensive assessments by major regulatory bodies have not established that typical human consumption of sucralose leads to the same harm in people. The distinctions between in vitro findings and in vivo human health outcomes, the role of manufacturing impurities versus metabolic byproducts, and the conservative nature of screening thresholds versus established acceptable daily intakes, are all crucial considerations in this complex scientific debate. Questions persist regarding specific compounds, conditions of exposure, and other potential biological effects, underscoring the dynamic nature of food science and the continuous need for rigorous investigation.
About the Author
